Compare QURE & AWF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | QURE | AWF |
|---|---|---|
| Founded | 1998 | 1993 |
| Country | Netherlands | United States |
| Employees | 248 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 864.9M |
| IPO Year | 2013 | N/A |
| Metric | QURE | AWF |
|---|---|---|
| Price | $26.64 | $10.21 |
| Analyst Decision | Buy | |
| Analyst Count | 14 | 0 |
| Target Price | ★ $45.00 | N/A |
| AVG Volume (30 Days) | ★ 1.6M | 458.8K |
| Earning Date | 05-05-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 7.57% |
| EPS Growth | ★ 29.67 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $13,107,000.00 | N/A |
| Revenue This Year | $126.12 | N/A |
| Revenue Next Year | $200.43 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $8.73 | $9.85 |
| 52 Week High | $71.50 | $11.43 |
| Indicator | QURE | AWF |
|---|---|---|
| Relative Strength Index (RSI) | 76.81 | 42.37 |
| Support Level | $22.59 | $9.99 |
| Resistance Level | $28.63 | $10.24 |
| Average True Range (ATR) | 1.80 | 0.10 |
| MACD | 0.89 | -0.03 |
| Stochastic Oscillator | 80.84 | 4.29 |
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.
Alliancebernstein Glb High Inc Fund Inc is a United States-based diversified, closed-end management investment company. Its primary investment objective is to seek high current income, and secondarily, capital appreciation. The fund invests in debt securities, including Sovereign Debt Obligations and corporate debt, denominated in non-U.S. currencies as well as in the U.S. Dollar. It may invest without limit in emerging and developed markets and debt securities of U.S. and non-U.S. corporate issuers.